Department of Biology, Texas A&M University, College Station, Texas 77843-3258, USA.
Curr Pharm Biotechnol. 2011 Aug;12(8):1255-62. doi: 10.2174/138920111796117292.
Invasive fungal infections are a serious threat to public health, particularly to people with compromised or suppressed immunity. Although the current antifungal therapies have been significantly improved, the outcome is still far from satisfactory, partly due the limited number of classes of clinically available antifungals, the development of resistance to current antifungals, and the challenges of proper and early diagnosis. Recent advances in the development of new antifungals, although still in the investigational stages, offer some new hope of improving the future of antifungal therapy. Here, we review literature regarding the antifungal activities of several FDA-approved drugs, which were originally intended for treating other conditions, as well as newly discovered natural/artificial compounds. We focus on their mechanisms of action, limitations, and potential in treating fungal infections. The diverse mechanisms of action of these compounds summarized here can provide new directions for future endeavors on antifungal drug development.
侵袭性真菌感染对公众健康构成严重威胁,特别是对免疫功能受损或抑制的人群。尽管目前的抗真菌治疗方法已经有了显著的改善,但治疗效果仍远不理想,部分原因是临床可用的抗真菌药物种类有限、对现有抗真菌药物的耐药性发展以及正确和早期诊断的挑战。最近在开发新的抗真菌药物方面的进展,尽管仍处于研究阶段,但为改善抗真菌治疗的未来提供了一些新的希望。在这里,我们回顾了一些原本用于治疗其他疾病的 FDA 批准药物以及新发现的天然/人工化合物的抗真菌活性的文献。我们重点介绍了它们的作用机制、局限性以及在治疗真菌感染方面的潜力。这里总结的这些化合物的不同作用机制为未来的抗真菌药物开发提供了新的方向。